CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
That’s just one of the reasons that National Blood Donor Month, which has taken place each Jan...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
We have now added a new section called the "Assay History List" to the "At A Gla...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...